Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | PTGFR | P43088 | 9/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708511 | 0.91 | MEN1 (0.41) | KMT2AMEN1ALDH1A1NSD2PTGFR | |
| SCHEMBL6710153 | 0.89 | TRPA1 (0.43) | KMT2AMEN1ALDH1A1NSD2FTO | |
| SCHEMBL6710479 | 0.89 | KMT2A (0.41) | KMT2AMEN1ALDH1A1NSD2PTGFR | |
| SCHEMBL6713931 | 0.87 | GRIK1 (0.41) | KMT2AMEN1NSD2GRIK1HIF1A | |
| SCHEMBL6713760 | 0.86 | GRIK1 (0.42) | KMT2AMEN1NSD2GRIK1HIF1A | |
| SCHEMBL6711794 | 0.85 | ALDH1A1 (0.46) | KMT2AMEN1ALDH1A1NSD2GRIK1 | |
| SCHEMBL6708757 | 0.85 | GRIK1 (0.42) | KMT2AMEN1NSD2GRIK1RXFP1 | |
| SCHEMBL6708679 | 0.84 | GRIK1 (0.44) | NSD2GRIK1HIF1ANPSR1RXFP1 | |
| SCHEMBL6709215 | 0.84 | MEN1 (0.55) | KMT2AMEN1ALDH1A1GRIK1NPSR1 | |
| SCHEMBL6710166 | 0.84 | NPC1 (0.43) | GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | KMT2A 3181/4885MEN1 4100/4885ALDH1A1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.